Global Search

Search articles, concepts, and chapters

OphthalmologyFebruary 202420 citations

Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study.

Rabiolo Alessandro, Montesano Giovanni, Crabb David P, Garway-Heath David F


AI Summary

This study found standard IOP fluctuations don't predict glaucoma progression, but mean IOP and ocular pulse amplitude might be more relevant for identifying faster progression.

Abstract

Purpose

To investigate whether intraocular pressure (IOP) fluctuation is associated independently with the rate of visual field (VF) progression in the United Kingdom Glaucoma Treatment Study.

Design

Randomized, double-masked, placebo-controlled multicenter trial.

Participants

Participants with ≥5 VFs (213 placebo, 217 treatment).

Methods

Associations between IOP metrics and VF progression rates (mean deviation [MD] and five fastest locations) were assessed with linear mixed models. Fluctuation variables were mean Pascal ocular pulse amplitude (OPA), standard deviation (SD) of diurnal Goldmann IOP (diurnal fluctuation), and SD of Goldmann IOP at all visits (long-term fluctuation). Fluctuation values were normalized for mean IOP to make them independent from the mean IOP. Correlated nonfluctuation IOP metrics (baseline, peak, mean, supine, and peak phasing IOP) were combined with principal component analysis, and principal component 1 (PC1) was included as a covariate. Interactions between covariates and time from baseline modeled the effect of the variables on VF rates. Analyses were conducted separately in the two treatment arms.

Main outcome measures

Associations between IOP fluctuation metrics and rates of MD and the five fastest test locations.

Results

In the placebo arm, only PC1 was associated significantly with the MD rate (estimate, -0.19 dB/year [standard error (SE), 0.04 dB/year]; P < 0.001), whereas normalized IOP fluctuation metrics were not. No variable was associated significantly with MD rates in the treatment arm. For the fastest five locations in the placebo group, PC1 (estimate, -0.58 dB/year [SE, 0.16 dB/year]; P < 0.001), central corneal thickness (estimate, 0.26 dB/year [SE, 0.10 dB/year] for 10 μm thicker; P = 0.01) and normalized OPA (estimate, -3.50 dB/year [SE, 1.04 dB/year]; P = 0.001) were associated with rates of progression; normalized diurnal and long-term IOP fluctuations were not. In the treatment group, only PC1 (estimate, -0.27 dB/year [SE, 0.12 dB/year]; P = 0.028) was associated with the rates of progression.

Conclusions

No evidence supports that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative. Ocular pulse amplitude may be an independent factor for faster glaucoma progression.

Financial disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.


MeSH Terms

HumansIntraocular PressureVisual FieldsDouble-Blind MethodDisease ProgressionAntihypertensive AgentsMaleFemaleTonometry, OcularAgedGlaucoma, Open-AngleUnited KingdomMiddle AgedVisual Field TestsVision DisordersLatanoprostCircadian Rhythm

Key Concepts5

In the placebo arm of the United Kingdom Glaucoma Treatment Study (213 participants), principal component 1 (PC1), combining baseline, peak, mean, supine, and peak phasing IOP, was significantly associated with the mean deviation (MD) rate of visual field progression (estimate, -0.19 dB/year [standard error (SE), 0.04 dB/year]; P < 0.001).

PrognosisRCTRandomized, double-masked, placebo-controlled multicenter trialn=213 participantsCh3Ch6

In the placebo arm of the United Kingdom Glaucoma Treatment Study (213 participants), normalized intraocular pressure (IOP) fluctuation metrics (diurnal fluctuation and long-term fluctuation) were not significantly associated with the mean deviation (MD) rate of visual field progression.

PrognosisRCTRandomized, double-masked, placebo-controlled multicenter trialn=213 participantsCh3Ch6

In the placebo arm of the United Kingdom Glaucoma Treatment Study (213 participants), principal component 1 (PC1) (estimate, -0.58 dB/year [SE, 0.16 dB/year]; P < 0.001), central corneal thickness (estimate, 0.26 dB/year [SE, 0.10 dB/year] for 10 μm thicker; P = 0.01), and normalized ocular pulse amplitude (OPA) (estimate, -3.50 dB/year [SE, 1.04 dB/year]; P = 0.001) were associated with the rates of progression for the fastest five visual field locations.

PrognosisRCTRandomized, double-masked, placebo-controlled multicenter trialn=213 participantsCh3Ch6

In the placebo arm of the United Kingdom Glaucoma Treatment Study (213 participants), normalized diurnal and long-term intraocular pressure (IOP) fluctuations were not associated with the rates of progression for the fastest five visual field locations.

PrognosisRCTRandomized, double-masked, placebo-controlled multicenter trialn=213 participantsCh3Ch6

In the treatment arm of the United Kingdom Glaucoma Treatment Study (217 participants), only principal component 1 (PC1), combining baseline, peak, mean, supine, and peak phasing IOP, was associated with the rates of progression for the fastest five visual field locations (estimate, -0.27 dB/year [SE, 0.12 dB/year]; P = 0.028).

PrognosisRCTRandomized, double-masked, placebo-controlled multicenter trialn=217 participantsCh3Ch6

Is this article assigned to the wrong chapter(s)? Let us know.